An interventional study of SABR in Colorectal Cancer, sponsored by IRCCS Sacro Cuore Don Calabria di Negrar. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by IRCCS Sacro Cuore Don Calabria di Negrar · Not applicable, Interventional, and Treatment
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological Radiotherapy and 18 other Italian centers.
The reason for this research study is to evaluate whether stereotactic radiotherapy treatment (SABR), in addition to the systemic chemotherapy treatment foreseen by clinical practice for low-intermediate risk oligometastatic colorectal cancer, is able to:
thus inducing an improvement in the quality of life of patients suffering from this type of pathology.
Therefore, as part of this randomized study, before starting first or second line systemic therapy for his tumor, the patient will be randomized to one of the following treatment arms:
The procedure that is intended to be tested in the experimental arm is a stereotactic radiotherapy treatment on oligometastases (up to a maximum of 3 sites), with ablative dosage (effective biological dose >100 Gy), performed before the start of systemic therapy of I or II line (at most within the second cycle of the same).
It is hoped that the addition of this type of radiotherapy will increase the potential clinical benefit of the treatment in the context of colorectal cancer.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's planned enrollment of 204 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →IRCCS Sacro Cuore Don Calabria di Negrar is the lead sponsor of 36 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
SABR to all the active sites of disease (1-3 oligometastases). 3D-CRT, IMRT and VMAT techniques are allowed, but IMRT and VMAT are strongly suggested.
Radiation: SABR
no SABR
A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data. In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered. SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest.
Progression-free survival (PFS).
PFS is defined as the time between randomization to the radiological evidence of disease progression. For patients with a PFS event, PFS will be calculated as the time interval from the date of randomization to the date of first objective evidence of disease progression or death from any cause, whichever occurs first. For patients without a PFS event, PFS will be censored at the date of the last radiographic assessment prior to the date of study end.
Time frame: 7 years
Time to the polymetastatic conversion (tPMC)
tPMC will be defined as the time between randomization to the date of radiological occurrence of \>5 new metastases. For patients without a tPMC event, time to tPMC will be censored at the date of the last radiographic assessment prior to the study end date.
Time frame: 7 years
Local control (LC): the time between randomization to the date of radiological development of local progression after SABR.
For patients without LC, time to LC will be censored at the date of the last radiographic assessment prior to the study end date.
Time frame: 7 years
Overall survival (OS)
OS will be defined as the time between randomization to the date of death or last follow-up. For patients who are alive at the time of the study end date, OS time will be censored on the last date the patient is known to be alive or the study end date, whichever occurs first.
Time frame: 7 years
Time to start of the next systemic treatment line (NEST)
For patients without a NEST, time to NEST will be censored at the date of the last patient visit before the study end date.
Time frame: 7 years
Number of adverse events as assessed by CTCAE v4.0
Number of adverse events as assessed by CTCAE v4.0
Time frame: 60 months
Number of acute side-effects
Acute side-effects
Time frame: from enrollment until 6 months after the last dose of SABR
Number of Late side-effects
Late side-effects
Time frame: from the 6 months after the last dose of SABR until up to 3 years after inclusion in the trial
questionnaire QLQ-C30
Quality of life (QoL): QoL will be evaluate with the questionnaire QLQ-C30
Time frame: 60 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Sacro Cuore Don Calabria di Negrar